US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.29 against a street estimate of 0.08 — a beat of 262.5%.
Analysts rate STAAR Surgical Company a hold (3 buy, 10 hold, 1 sell out of 14) with an average price target of $28.89.
| Fund | Stake |
|---|---|
| BROADWOOD CAPITAL Inc | 32.38% |
| BlackRock Inc | 13.39% |
| Yunqi Capital Ltd | 6.54% |
| Madison Avenue Partners, LP | 4.90% |
| Vanguard Portfolio Management, LLC | 4.27% |
| State Street Corp | 3.68% |
| Vanguard Capital Management, LLC | 3.40% |
| Anatole Investment Management Ltd | 3.22% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-06-22 |
| Board / officer change · Q2 2026 | 2026-06-09 |
| Quarterly report · Q2 2026 | 2026-05-13 |
| Results announced · Q2 2026 | 2026-05-13 |
| Proxy statement · Q2 2026 | 2026-05-04 |
| Reg FD disclosure · Q2 2026 | 2026-04-08 |
| Annual report FY2026 | 2026-03-03 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for STAAR Surgical Company — free to start.
Google PlayApp StoreData updated 2026-08-05.